Market Cap: $2.6B
ZL
Zai Lab Limited
ZLAB
NASDAQ (NASDAQ Global Market)USD
Market Cap: $2.6B
Zai Lab, a growing force in the pharmaceutical sector, unveils significant advancements in its clinical and preclinical pipelines. This development underscores the company’s potential impact in areas…
Zai Lab Limited announces a strategic collaboration with Amgen Inc. that aims to enhance treatment options for patients suffering from extensive-stage small cell lung cancer (SCLC). This partnership i…
Zai Lab's Strategic Shift in Biopharmaceuticals: A Bright Future Ahead Zai Lab (NASDAQ: ZLAB) demonstrates a significant upward trajectory in its latest quarterly earnings report, released on February…
Zai Lab’s Q4 Earnings Showcase Growth in Biopharma Pipeline Zai Lab, a biopharmaceutical company specializing in oncology and autoimmune diseases, recently announces its Q4 earnings for 2026, demonstr…
Regulatory Momentum Helps Zai Lab and Peers Accelerate Oncology Programs Regulators’ shift toward expedited pathways for targeted cancer therapies is creating a faster development environment that ben…
Regulatory acceleration strengthens Zai Lab’s oncology playbook Zai Lab Faces Faster Regulatory Path for Biomarker‑Driven Oncology Programs Zai Lab is operating in an oncology environment where U.S. r…
Zai Lab's Strategic Positioning in a Competitive Biopharmaceutical Landscape Zai Lab stands at a pivotal juncture in the biopharmaceutical industry as it continues to expand its portfolio and strength…
Zai Lab: Focusing on Innovation Amidst a Competitive Landscape Zai Lab continues to position itself as a key player in the biopharmaceutical industry, with an emphasis on developing innovative therapi…
Zai Lab's Strategic Focus on Innovative Therapies in Oncology Zai Lab, a biotechnology company specializing in innovative therapies for cancer and other diseases, continues to advance its mission to i…
Zai Lab Advances Cancer Treatment with Bemarituzumab Trial Completion Zai Lab, in partnership with Amgen Inc., announces the completion of the final analysis of the Phase 3 FORTITUDE-101 trial, which…
Zai Lab and Amgen Advance Gastric Cancer Treatment with Bemarituzumab Analysis Zai Lab, in partnership with Amgen Inc., announces a pivotal development in the fight against gastric cancer with the com…
Oncolytics Biotech Advances Immunotherapy for Pancreatic Cancer Oncolytics Biotech Inc. is positioning itself as a key player in the oncology sector with its investigational immunotherapy, pelareorep,…
Oncolytics Biotech Advances Immunotherapy for Pancreatic Cancer Oncolytics Biotech Inc. is making significant progress in the oncology sector with its investigational immunotherapy, pelareorep, aimed…
Zai Lab's KarXT Receives NMPA Acceptance, Paving the Way for Innovative Schizophrenia Treatment in China Zai Lab Limited announces a significant milestone as China's National Medical Products Administ…
Zai Lab's Breakthrough in Schizophrenia Treatment: KarXT's NDA Acceptance Marks a New Era Zai Lab Limited has achieved a significant milestone with the acceptance of the New Drug Application (NDA) for…
Zai Lab Strengthens Immunology Portfolio through Collaboration with Vertex Pharmaceuticals Zai Lab Limited has announced an exclusive collaboration with Vertex Pharmaceuticals for the development and…
Zai Lab Strengthens Oncology Pipeline with MediLink Collaboration Zai Lab Limited has announced a strategic collaboration with MediLink Therapeutics (Suzhou) Co., Ltd., focusing on the development of…
Zai Lab Expands Oncology Pipeline with MediLink Collaboration Zai Lab Limited announces a strategic partnership with MediLink Therapeutics (Suzhou) Co., Ltd. aimed at developing ZL-6201, a novel antib…
Zai Lab Prepares for Key Presentation at J.P. Morgan Healthcare Conference Zai Lab Limited, a leading biopharmaceutical company known for its focus on innovative therapies, announces participation in…
Zai Lab to Highlight Innovations at Upcoming Healthcare Conference Zai Lab Limited, a prominent biopharmaceutical company operating in both China and the United States, prepares to showcase its advanc…
Zai Lab Expands Patient Access with Inclusion in National Reimbursement Drug List Zai Lab Limited announces a significant milestone in its commitment to enhancing patient access to innovative therapie…
Zai Lab Expands Patient Access to Innovative Cancer Treatments in China Zai Lab Limited, a prominent biopharmaceutical company, announces the inclusion of several of its therapeutic products in the 20…
Zai Lab Partners with Pfizer to Combat Antimicrobial Resistance in China Zai Lab Ltd. announces a pivotal strategic collaboration with Pfizer to commercialize XACDURO® (sulbactam-durlobactam) in mainl…
Zai Lab and Pfizer Forge Strategic Alliance to Tackle Antimicrobial Resistance Zai Lab Ltd has announced a strategic collaboration with Pfizer to commercialize XACDURO® (sulbactam-durlobactam) in main…
Zai Lab's Strategic Public Offering Fuels Growth Initiatives Zai Lab Ltd. underscores its commitment to growth and innovation in the biopharmaceutical sector with the recent announcement of its underw…